Snowball logo
logo
6855_logo

Ascentage Pharma Grp International

HK$24.78-HK$0.84ย  (3.28%)
Estimate
Beta
0.771
Growth
Revenue, YoY
-63.82%
Net income, YoY
-594.12%
FCF, YoY
-64.62%
Forecast
EPS (FWD)
-0.33
About the company
Ticker
6855
ISIN
KYG0519B1023
Country
China
Sector (GICS)
Healthcare
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Frequently asked questions

What sector does Ascentage Pharma Grp International (6855) operate in?

Ascentage Pharma Grp International belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Ascentage Pharma Grp International (6855) current stock price?

As of the latest data, Ascentage Pharma Grp International stock price is HK$24.78, with a previous close of HK$25.62. Ascentage Pharma Grp International lost -HK$0.84 in the last trading session, representing a -3.28% loss.

What is Ascentage Pharma Grp International (6855) current market capitalization?

Ascentage Pharma Grp International market cap is approximately 9.26 billion.

What is Ascentage Pharma Grp International (6855) EBITDA?

Ascentage Pharma Grp International EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -699.11 million.

Does Ascentage Pharma Grp International (6855) pay dividends?

No. Ascentage Pharma Grp International does not pay a dividend.

What is Ascentage Pharma Grp International (6855) beta (volatility) score?

Ascentage Pharma Grp International has a beta of 0.771, indicating lower volatility than the overall market.